Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

22.65
-0.6400-2.75%
Post-market: 22.650.00000.00%19:15 EDT
Volume:2.68M
Turnover:61.08M
Market Cap:1.44B
PE:-7.55
High:23.38
Open:23.19
Low:22.28
Close:23.29
Loading ...

Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment

TIPRANKS
·
02 Jun

BRIEF-Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy

Reuters
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing

Reuters
·
02 Jun

Top Premarket Gainers

MT Newswires Live
·
02 Jun

Vera Therapeutics Shares Extend Premarket Gains, Last up 65.5%

THOMSON REUTERS
·
02 Jun

BUZZ-Vera Therapeutics jumps after kidney disease drug succeeds in late-stage trial

Reuters
·
02 Jun

Vera Therapeutics Announces Positive Phase 3 Trial Results

TIPRANKS
·
02 Jun

Vera Therapeutics Shares Jump 36.7% Premarket After Kidney Disease Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
02 Jun

Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept

TIPRANKS
·
02 Jun

Vera Therapeutics Announces Successful Completion of Phase 3 Trial for Atacicept; Plans to Submit BLA for FDA Approval in IgA Nephropathy by Q4 2025

Reuters
·
02 Jun

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in Origin Phase 3 Trial in Adults With Iga Nephropathy

THOMSON REUTERS
·
02 Jun

Vera Therapeutics Inc - to Submit Bla for Atacicept to FDA in 4Q 2025

THOMSON REUTERS
·
02 Jun

Cantor Fitzgerald Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
29 May

Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential

TIPRANKS
·
23 May

Evercore ISI Remains a Buy on Vera Therapeutics (VERA)

TIPRANKS
·
08 May

Vera Therapeutics Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
07 May

Vera Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Vera Therapeutics price target lowered to $26 from $34 at Wedbush

TIPRANKS
·
07 May

Vera Therapeutics Inc : Wedbush Cuts Target Price to $26 From $34

THOMSON REUTERS
·
07 May

Vera Therapeutics: Strong Financials and Promising Clinical Developments Support Buy Rating

TIPRANKS
·
07 May